Demant (WILYY) AI Stock Analysis

Demant

(Other OTC:WILYY)

Select Model

Rating:68Neutral

Price Target:$30.00▲(9.93% Upside)

Action:reiterated

Date:08/19/26

Upgraded earnings guidance and bullish technical momentum are the primary supports, partially offset by mixed financials with high debt and stretched valuation.

Positive Factors

Strong growth outlookStrong organic growth and an upgraded outlook indicate continued demand for Demant’s hearing healthcare products and services. This momentum can support operating scale, reinforce market position, and provide a durable base for revenue expansion over the next several quarters.

Negative Factors

Elevated leverageThe more debt-heavy capital structure reduces financial flexibility and leaves less room to absorb weaker earnings or unexpected costs. Higher leverage can also increase refinancing sensitivity and constrain capital allocation while Demant completes integration and savings programs.

Demant (WILYY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $11.49B
Dividend Yield: ―
Average Volume (3M): 1,665
Price to Earnings (P/E): 47.4
Beta (1Y): 0.90
Revenue Growth: 17.46%
EPS Growth: -23.56%
Country: US
Employees: 26,704
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Demant Business Overview & Revenue Model

Company Description

Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers...

How the Company Makes Money

Demant makes money primarily by selling hearing healthcare products and by providing hearing care services. A major revenue stream is the sale of hearing aids and associated accessories and solutions, which are sold through hearing care professionals...

Demant Earnings Call Summary

Earnings Call Date:Aug 10, 2026(Q2-2026)|% Change Since:27.52%|Next Earnings Date:Feb 08, 2027

Earnings Call SentimentPositive

The call presented multiple strong operational and financial positives: robust reported revenue growth (15%), gross profit expansion (+17%) and gross margin improvement (+1.1 ppt), solid cash generation, successful commercial momentum driven by Oticon Zeal and the new Oticon Reveal product positioning, and upgraded full-year guidance. Offsetting these positives are elevated and increased special items tied to acquisitions and restructurings, FX headwinds, regional softness (notably China and managed care in the U.S.), and the risk of competitive launches in H2. On balance, the company’s financial performance, product momentum, successful integration progress and strengthened outlook outweigh the headwinds and one-off costs.

Positive Updates

Strong Reported Revenue Growth

Group reported revenue growth of 15% in H1 2026, composed of 7% organic growth, 10% acquisitive growth (predominantly from KIND), and a -3% FX effect.

Negative Updates

Increased Special Items and Integration Costs

Special items for full-year 2026 were increased to DKK 400 million (from DKK 325 million). KIND integration costs are now estimated at DKK 150 million (up from DKK 125 million) and cost-savings implementation severance/implementation costs at DKK 250 million (up from DKK 200 million). H1 special items totaled DKK 216 million (predominantly KIND).

Company Guidance

Management upgraded 2026 guidance: organic revenue growth is now expected at 6–7% (up from 3–6%) and EBIT before special items at DKK 4.4–4.8bn. They also set total special items at DKK 400m (up from DKK 325m), with KIND integration costs of DKK 150m (was DKK 125m) and cost‑saving implementation costs of DKK 250m (was DKK 200m); the cost‑effectiveness program is now expected to deliver DKK 300m (vs DKK 250m) and KIND is forecast to contribute DKK 325m to EBIT (vs DKK 300m), while a tariff refund of DKK 25m is expected in H2. For context H1 performance underpinning the upgrade included reported group revenue +15% (organic +7%, acquisitive +10%, FX -3%), gross profit ~DKK 10bn (+17%, gross margin +1.1pp), EBIT before special items DKK 2.134bn (16.5% margin), cash flow from operations DKK 1.6bn (+6%), and net leverage down to ~3.0 with an expectation to be slightly above the 2.0–2.5 target range by year‑end.

Demant Financial Statement Overview

Summary

Mixed performance with strong gross margins but inconsistent revenue growth, declining net profit margins, and rising debt levels pushing leverage higher.

Income Statement

72Positive

Balance Sheet

58Neutral

Cash Flow

65Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	24.98B	22.97B	22.42B	22.44B	19.70B	17.91B
Gross Profit	19.08B	17.37B	17.09B	16.54B	14.67B	13.46B
EBITDA	5.99B	5.43B	5.80B	5.75B	4.29B	4.48B
Net Income	1.64B	1.54B	2.39B	1.79B	2.08B	2.51B
Balance Sheet
Total Assets	40.03B	39.07B	32.45B	30.55B	29.86B	24.86B
Cash, Cash Equivalents and Short-Term Investments	1.50B	1.33B	1.11B	1.14B	1.13B	1.17B
Total Debt	20.28B	20.99B	15.68B	14.45B	15.08B	11.34B
Total Liabilities	28.71B	29.16B	22.81B	21.21B	21.30B	16.88B
Stockholders Equity	11.24B	9.84B	9.56B	9.26B	8.56B	7.98B
Cash Flow
Free Cash Flow	3.47B	3.18B	3.30B	3.58B	1.70B	2.55B
Operating Cash Flow	4.08B	3.80B	4.08B	4.23B	2.62B	3.27B
Investing Cash Flow	-6.09B	-6.79B	-1.83B	-1.77B	-3.33B	-1.30B
Financing Cash Flow	2.50B	3.23B	-2.24B	-2.41B	934.00M	-1.78B

Demant Technical Analysis

Technical Analysis SentimentPositive

Last Price27.29

Price Trends

50DMA24.31Positive

100DMA22.68Positive

200DMA19.52Positive

Market Momentum

MACD0.89Positive

RSI69.72Neutral

STOCH86.58Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WILYY, the sentiment is Positive. The current price of 27.29 is above the 20-day moving average (MA) of 26.30, above the 50-day MA of 24.31, and above the 200-day MA of 19.52, indicating a bullish trend. The MACD of 0.89 indicates Positive momentum. The RSI at 69.72 is Neutral, neither overbought nor oversold. The STOCH value of 86.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WILYY.

Demant Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

WILYY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	73Outperform	$30.69B	31.77	36.50%	―	13.03%	40.88%
GEHC	71Outperform	$34.62B	19.84	16.13%	0.19%	6.87%	-2.26%
PHG	69Neutral	$26.40B	20.72	10.05%	3.68%	―	―
ZBH	69Neutral	$18.03B	22.89	6.36%	1.02%	8.62%	0.09%
WILYY	68Neutral	$11.18B	47.39	15.31%	―	17.46%	-23.56%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
COCH	44Neutral	$51.31M	-0.98	1719.71%	―	-6.76%	42.70%

* General Sector Average

Performance Comparison

WILYY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
WILYY	Demant A/S Unsponsored ADR	27.29	10.51	62.62%
DXCM	Dexcom	82.29	21.86	36.17%
PHG	Koninklijke Philips N.V.	26.92	0.58	2.19%
ZBH	Zimmer Biomet Holdings	94.52	-4.30	-4.35%
COCH	Envoy Medical, Inc. Class A	6.63	-1.01	-13.19%
GEHC	Ge Healthcare Technologies Inc.	76.57	2.25	3.03%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 19, 2026

Demant AI Stock Analysis